Provenge (sipuleucel-T) is a brand-name injectable drug prescribed for a type of metastatic prostate cancer in adults. The cost of the drug, with and without insurance, can depend on several factors, ...

Data from the studies revealed that Provenge treatment results in antigen spread associated with overall survival benefits. Moreover, Dendreon presented data from the phase IV PROCEED study on ...

A new survey of cancer doctors published in a research note from investment bank R.W. Baird provides some more reasons for investors to worry about Dendreon and its prostate cancer treatment Provenge, ...

Provenge (sipuleucel-T) is a brand-name drug that’s prescribed to treat a type of advanced prostate cancer in certain adults. Provenge comes as a liquid that’s typically given as an intravenous (IV) ...

May 3, 2010 — Clinicians are likely to be hearing from patients about sipuleucel-T (Provenge, Dendreon), the immunotherapy that has just been approved by the US Food and Drug Administration (FDA) for ...

NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S.

NEW YORK (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators and ...

Much has been said and written about the circumstances surrounding the launch of Dendreon’s innovation in cancer treatment, Provenge, a novel immunotherapeutic treatment for end-stage prostate cancer.

September 29, 2011 — A series of media reports in the past few weeks have detailed mounting problems at Dendreon, the Seattle, Washington–based maker of the immunotherapy sipuleucel-T (Provenge), ...

Amidst controversy, the FDA finally approved the controversial prostate cancer therapy. Hopes are high that Provenge represents the first in a long line of effective immunotherapeutics. Amidst ...

The European Commission (EC) has recently granted marketing authorization for Dendreon Corporation's (DNDN) Provenge. The drug is approved in the EU for the treatment of asymptomatic or minimally ...